Vonoprazon Fumarate API Manufacturers in India (Business Opportunities - Marketing & Sales)

INNetAds > Business Opportunities > Marketing & Sales

Item ID 3188533 in Category: Business Opportunities - Marketing & Sales

Vonoprazon Fumarate API Manufacturers in India


Contact Shobha Life Sciences immediately if you require vonoprazan fumarate API manufacturers operating in India who adhere to strict deadlines and provide premium-quality chemicals. Founded in the year 2021, we are a dynamic and innovative pharmaceutical company dedicated to the research, development, and manufacturing of high-quality and affordable drugs that improve patient health and well-being. We are a specialist preclinical contract research organisation providing facilities for various preclinical experiments like stability studies, pharmacokinetic, pharmacodynamic, toxicological, and efficacy studies.

Over the years, we have directed our focus on addressing unmet medical needs of patients while delivering a wide range world-class drugs for varied healthcare applications. It is our unwavering commitment to provide safe, effective, and low-costing pharmaceutical products that will help improve health and lives around the globe.

Medical patients use Vonoprazan Fumarate to treat the symptoms of heartburn together with acid reflux and stomach ulcers. This particular drug differs from antacids and proton pump inhibitors (PPIs) since it provides better immediate benefits and extended relief through its capability to effectively block stomach acid production. This medication provides excellent benefits to patients who need stronger acid control or who lack adequate responses to typical treatments.


Related Link: Click here to visit item owner's website (0 hit)

Target State: Andhra Pradesh
Target City : Hyderabad
Last Update : 06 June 2025 4:10 PM
Number of Views: 81
Item  Owner  : Shobha
Contact Email:
Contact Phone: 9121212469

Friendly reminder: Click here to read some tips.
INNetAds > Business Opportunities > Marketing & Sales
 © 2025 INNetAds.com
2025-07-31 (0.431 sec)